"rationale","versionIdentifier","uuid:ID","instanceType","id"
"The discontinuation rate associated with this oral dosing regimen was 58.6% in previous studies, and alternative clinical strategies have been sought to improve tolerance for the compound. To that end, development of a Transdermal Therapeutic System (TTS) has been initiated.","2","72de1775-9edb-4256-814c-4791e0fd532d","StudyVersion","StudyVersion_1"
